[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635420":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":9,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Picankibart in Palmoplantar Pustulosis","EXPERIMENTAL",null,[13],"Drug: Picankibart",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Picankibart","Induction phase: Picankibart 200 mg administered subcutaneously at Weeks 0, 4, and 8.\n\nMaintenance phase: Picankibart 100 mg administered subcutaneously at Weeks 20, 32, and 44.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Shuai Shao","CONTACT","8619249282690","2269744794@qq.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China","RECRUITING","Xi'an","Shaanxi","710032","China","CN",{"type":36,"coordinates":37},"Point",[38,39],108.92861,34.25833,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":24,"phoneExt":11,"email":25},"Shuai Shao, MD PhD",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635420","picankibart-in-palmoplantar-pustulosis-100635420",false,"NCT07552454","Efficacy and Safety of Picankibart in the Treatment of Moderate-to-Severe Palmoplantar Pustulosis: A Prospective, Single-Arm, Open-Label Clinical Study","Inclusion Criteria:\n\n* Aged 18-65 years, regardless of gender. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and\u002For skin histopathology.\n\nFailed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.\n\nConsidered suitable for treatment with picankibart as assessed by the clinician.\n\nVoluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with active hepatitis B, hepatitis C, or tuberculosis. Pregnant patients or those planning pregnancy within 6 months. Subjects unable to comply with follow-up as required by the study protocol. Other conditions deemed unsuitable for this study.","ALL","18 Years","65 Years",{"count":56,"type":57},60,"ESTIMATED","INTERVENTIONAL",[60],"NA","1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects.\n2. Study Subjects\n\nInclusion Criteria\n\n1. Aged 18-65 years, regardless of gender.\n2. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and\u002For skin histopathology.\n3. Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions.\n4. Considered suitable for treatment with Picankibart as assessed by the clinician.\n5. Voluntarily participate in the study and provide written informed consent.\n\nExclusion Criteria\n\n1. Patients with active hepatitis B, hepatitis C, or tuberculosis.\n2. Pregnant patients or those planning pregnancy within 6 months.\n3. Subjects unable to comply with follow-up as required by the study protocol.\n4. Other conditions deemed unsuitable for this study.\n\nWithdrawal Criteria\n\n1. Subjects may withdraw from the study at any time for any reason.\n2. Occurrence of a serious adverse event or intolerable adverse event.\n3. Development of any item listed in the exclusion criteria during the study.\n4. The investigator may decide subject withdrawal for medical reasons.",[63],"Palmoplantar Pustulosis","2026-04-20",{"date":66,"type":67},"2026-04-27","ACTUAL",{"date":69,"type":57},"2026-04-15",{"date":71,"type":57},"2027-12-31",{"name":5,"class":6},1]